Official ESCRS | European Society of Cataract & Refractive Surgeons
Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert


Search Title by author or title

Impact of surgery cost on patient acceptance of multifocal intraocular lenses: multi-site questionnaire survey of Japanese candidate patients

Poster Details

First Author: K.Minami JAPAN

Co Author(s):    H. Bissen-Miyajima   T. Kanzaki   N. Yoshida              

Abstract Details


In Japan, the use of approved multifocal intraocular lens (MF-IOL) is not covered by federal insurance and the cost of surgery is out of pocket. Under this circumstance, the prevalence of MF-IOL implantations is limited under 2 % of total cataract surgeries. The impact of the surgery cost on patient acceptance of MF-IOL was assessed in candidate patients for cataract surgery with MF-IOL implantation through a multi-site questionnaire survey.


Eleven surgical sites, Japan


In November and December, 2016, candidates of MF-IOL implantation received questionnaire at 11 clinics. The questionnaire inquired acceptance of MF-IOL implantation after explanations of the benefits and potential complications (glare, halo, and contrast degradation) followed by the additional cost (approx. 3,000-4,000 Euro/eye). The respondents were directly collected to a third party institute by mail for analysis.


There were 238 respondents for the issues of 240 and 77% of patients were 60 years or older. With explanation of the clinical benefits and risk, 75 % of patients preferred an implantation of MF-IOL. After the cost of MF-IOL implantation was provided, the preferences decreased to 54%. This trend did not alter with sex, age, use of spectacles, and incomes. The current cost was accepted by 22% of 238 patients, among which the acceptance of 178 patients who preferred the MF-IOL before providing the cost was about 30%.


The questionnaire survey for candidate patients showed that the cost was a critical factor in the MF-IOL selection, and understanding the clinical benefit and risk could increase the acceptance.

Financial Disclosure:

is employed by a for-profit company with an interest in the subject of the presentation, research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented

Back to Poster listing